Kite Pharma (KITE) Posts Q4 Loss of 85c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Jefferies Reiterates Buy on Kite Pharma (KITE) Following a Mixed 4Q - PT to $75
March 1, 2016 9:31 AM ESTJefferies maintained a Buy rating on Kite Pharma (NASDAQ: KITE), and cut the price target to $75.00 (from $92.00), following the company's 4Q earnings conference call. KITE reported Q4 revenues of $4.9M, coming in ahead of Jefferies' estimate of $4.4M. GAAP EPS of ($0.85) also beat estimates... More
Citi Starts Kite Pharma (KITE) at Buy
February 25, 2016 8:25 AM ESTCiti initiatesd coverage on Kite Pharma (NASDAQ: KITE) with a Buy rating and a price target of $67.00.
For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.
Shares of Kite Pharma closed at $44.97 yesterday.
... More